Related Experiment Videos
Dideoxyinosine-induced pancreatitis in human immunodeficiency virus-infected children
T L Levin1, W E Berdon, H B Tang
1Department of Radiology, Division of Pediatric Radiology, Babies and Children's Hospital of New York-Columbia Presbyterian Medical Center, 3959 Broadway, BHN 3-318, New York, NY 10032, USA.
Pediatric Radiology
|February 1, 1997
Insights
Dideoxyinosine (ddI), an HIV treatment, can cause pancreatitis. This report details two cases, including one with a rapidly developing pseudocyst, highlighting a serious adverse effect.
Area of Science:
- Infectious Diseases
- Pharmacology
- Gastroenterology
Background:
- Dideoxyinosine (ddI) is a nucleoside reverse transcriptase inhibitor used in HIV therapy.
- Antiretroviral therapy aims to suppress HIV replication and manage infection.
- Pancreatitis is a known, potentially severe adverse event associated with ddI.
Observation:
- Two distinct cases of pancreatitis in patients receiving ddI treatment are presented.
- One case demonstrated a rapid progression to pancreatic pseudocyst formation.
Findings:
- The cases underscore the risk of serious pancreatic complications with ddI use.
- Rapid pseudocyst development indicates a severe inflammatory response.
Implications:
- Clinicians should be vigilant for pancreatitis symptoms in patients on ddI.
- Early recognition and management are crucial to mitigate severe outcomes like pseudocyst formation.
- This highlights the importance of monitoring for adverse drug reactions in HIV treatment.
Abstract:
Dideoxyinosine (ddI) is a widely used antiretroviral agent in treatment of HIV infection. Pancreatitis is a serious side effect. Two cases are reported, one with rapid development of a pseudocyst.